搜索
Sutro Biopharma Inc
STRO添加自选
38.970USD
+0.550+1.43%
收盘 05/15, 16:00（美东）报价延迟15分钟
645.75M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.43%
5天
-3.16%
1月
+32.78%
6月
+330.70%
今年开始到现在
+236.82%
1年
+327.49%
TradingKey Sutro Biopharma Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Sutro Biopharma Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名113/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价33.30。中期看，股价处于上升通道。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sutro Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Sutro Biopharma Inc亮点
亮点风险
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
利润高增长
公司净利润处于行业前列，最新年度总收入102.48M美元
估值低估
公司最新PE估值-2.39，处于3年历史低位
机构加仓
最新机构持股7.58M股，环比增加2.79%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值17.16K
分析师目标
根据
12
位分析师
买入
评级
33.300
目标均价
-13.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sutro Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sutro Biopharma Inc简介
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
公司代码STRO
公司Sutro Biopharma Inc
CEOChung (Jane)
网址https://www.sutrobio.com/
相关品种
